Esperion Therapeutics ESPR Deferred Tax Assets, Operating Loss Carryforwards
Deferred Tax Assets, Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred tax assets, operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred tax assets, operating loss carryforwards?
- Esperion Therapeutics (ESPR) reported deferred tax assets, operating loss carryforwards of $211.53M in Q4 2025.
- How has Esperion Therapeutics's deferred tax assets, operating loss carryforwards changed year-over-year?
- Esperion Therapeutics's deferred tax assets, operating loss carryforwards increased by 3.7% year-over-year, from $203.89M to $211.53M.
- What is the long-term trend for Esperion Therapeutics's deferred tax assets, operating loss carryforwards?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred tax assets, operating loss carryforwards has grown at a 4.2% compound annual growth rate (CAGR), from $172.53M to $211.53M.